



The Role of the Immune System in Systemic Sclerosis

Guest Editor:

Dr. Takemichi Fukasawa

Department of Dermatology,
Graduate School of Medicine,
The University of Tokyo, Tokyo
113-8655, Japan

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editor

Dear Colleagues,

Systemic sclerosis is a systemic inflammatory disease that begins with immune abnormalities and leads to vascular damage and fibrosis. Although basic research has typically focused on B cells, vascular endothelial cells, and fibroblasts, systemic sclerosis research has made rapid progress, especially in recent years. Reasons for these advances include technological advances such as single cell analysis, as well as advances in clinical and translational research. These rapid advances have left no doubt surrounding the involvement of inflammatory cytokines and immune abnormalities in the pathogenesis of systemic sclerosis. This Special Issue, entitled "The Role of the Immune System in Systemic Sclerosis", aims to advance research on the involvement of the immune system in systemic sclerosis research.

Dr. Takemichi Fukasawa

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)